GenVec to receive $2.3M from NIAID for HIV vaccine candidate production

Sep 26 2009NewsGuard 100/100 Score

GenVec, Inc. (Nasdaq: GNVC) announced today that the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), has executed its third option period (year four) under a previously announced, five-year contract with GenVec valued at up to $52 million for the production of HIV vaccines.

GenVec will receive up to $2.3 million for the fourth year, which will support the generation of HIV vaccine candidates with GenVec's alternate adenovirus serotype technology.

www.genvec.com

Posted in: Pharmaceutical News

Tags: , , , , , , , , , , , , ,

Comments (1)

Suggested Reading

Community partnerships lead to more inclusive health care for neurodiverse individuals
Historical redlining continues to affect HIV treatment in affected communities
Research suggests no need for yellow fever vaccine booster after initial dose
Study uncovers key mechanism behind HIV latency
Cleveland Clinic presents new findings on triple-negative breast cancer vaccine
Pfizer-BioNTech vaccine provides strong protection against MIS-C in children aged 5–17
New nasal vaccine could help stop the spread of whooping cough
Innovative vaccine shields livestock from four strains of foot and mouth disease

Comments

  1. HIV vaccine
    Carl Horton Carl Horton United States says:
    September 26, 2009 at 8:47 AM

    I'm very glad to hear that HIV vaccine is on the way now maybe I can live normal life. Can I please be notified upon realease of vaccine?

    Reply
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Argonne receives $21.7 million to advance cancer and vaccine discoveries